Prevention of mammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanate

Cancer Research

Volumn 69, Issue 24, 2009, Pages 9473-9480

  Warin, Renaud ^a   Chambers, William H ^c   Potter, Douglas M ^b   Singh, Shivendra V ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYL ISOTHIOCYANATE; KI 67 ANTIGEN; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST HYPERPLASIA; CANCER INCIDENCE; CANCER PREVENTION; CD3+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DIET SUPPLEMENTATION; DRUG EFFICACY; EX VIVO STUDY; FEMALE; IN VIVO STUDY; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; VEGETABLE;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CADHERINS; CELL GROWTH PROCESSES; CELL TRANSFORMATION, VIRAL; DIET; FEMALE; ISOTHIOCYANATES; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ERBB-2; T-LYMPHOCYTES;

EID: 73649091148     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2960     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. DeSantis C, Jemal A, Ward E, Thun MJ. Temporal trends in breast cancer mortality by state and race. Cancer Causes Control 2008;19:537-45.
3. van de Ven SM, Elias SG, van den Bosch MA, Luijten P, Mali WP. Optical imaging of the breast. Cancer Imaging 2008;8:206-15.
4. Munoz M, Estevez LG, Alvarez I, et al. Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. Cancer Treat Rev 2008;34:701-9.
5. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36-47.
6. Hulka BS, Stark AT. Breast cancer: cause and prevention. Lancet 1995;346:883-7.
7. Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health 1996;17:47-67.
8. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
9. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24.
10. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-37.
11. Fowke JH, Chung FL, Jin F, et al. Urinary isothiocyanate levels, brassica, and human breast cancer. Cancer Res 2003;63:3980-6.
12. Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y, Shields PG. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr 2004;134:1134-8.
13. Hecht SS. Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev 2000;32:395-411.
14. Conaway CC, Yang YM, Chung FL. Isothiocyanates as cancer chemopreventive agents: their biological activities and metabolism in rodents and humans. Curr Drug Metab 2002;3:233-55.
15. Wattenberg LW. Inhibitory effects of benzyl isothiocyanate administered shortly before diethylnitrosamine or benzo(a)pyrene on pulmonary and forestomach neoplasia in A/J mice. Carcinogenesis 1987;8:1971-3.
16. Sugie S, Okumura A, Tanaka T, Mori H. Inhibitory effects of benzyl isothiocyanate and benzyl thiocyanate on diethylnitrosamine-induced hepatocarcinogenesis in rats. Jpn J Cancer Res 1993;84:865-70.
17. Yang YM, Conaway CC, Chiao JW, et al. Inhibition of benzo(a) pyrene-induced lung tumorigenesis in A/J mice by dietary N-acetylcysteine conjugates of benzyl and phenethyl isothiocyanates during the postinitiation phase is associated with activation of mitogen-activated protein kinases and p53 activity and induction of apoptosis. Cancer Res 2002;62:2-7.
18. Xiao D, Vogel V, Singh SV. Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak. Mol Cancer Ther 2006;5:2931-45.
19. Xiao D, Powolny AA, Singh SV. Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger ROS-dependent apoptosis in human breast cancer cells. J Biol Chem 2008;283:30151-63.
20. Jiao D, Eklind KI, Choi CI, Desai DH, Amin SG, Chung FL. Structure-activity relationships of isothiocyanates as mechanism-based inhibitors of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Res 1994;54:4327-33.
21. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci US A 1992;89:10578-82.
22. Singh SV, Warin R, Xiao D, et al. Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res 2009;69:2117-25.
23. Lenferink AE, Magoon J, Cantin C, O'Connor-McCourt MD. Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-β and Neu pathway signaling studies: identification of a novel model for TGF-β-induced epithelial-to-mesenchymal transition. Breast Cancer Res 2004;6:R514-30.
24. Giezeman-Smits KM, Okada H, Brissette-Storkus CS, et al. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4- transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 2000;60:2449-57.
25. Brissette-Storkus CS, Kettel JC, Whitham TF, et al. Flt-3 ligand (FL) drives differentiation of rat bone marrow-derived dendritic cells expressing OX62 and/or CD161 (NKR-P1). J Leukoc Biol 2002;71:941-9.
26. Hecht SS, Kenney PMJ, Wang M, Upadhyaya P. Benzyl isothiocyanate: an effective inhibitor of polycyclic aromatic hydrocarbon tumorigenesis in A/J mouse lung. Cancer Lett 2002;187:87-94.
27. Hecht SS, Kenney PM, Wang M, Trushin N, Upadhyaya P. Effects of phenethyl isothiocyanate and benzyl isothiocyanate, individually and in combination, on lung tumorigenesis induced in A/J mice by benzo(a)pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Lett 2000;150:49-56.
28. Boysen G, Kenney PM, Upadhyaya P, Wang M, Hecht SS. Effects of benzyl isothiocyanate and 2-phenethyl isothiocyanate on benzo(a)pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone metabolism in F-344 rats. Carcinogenesis 2003;24:517-25.
29. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
30. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
31. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 2003;19: 207-35.
32. Terabe M, Berzofsky JA. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol 2007;28:491-6.
33. Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-11.
34. Georgiannos SN, Renaut A, Goode AW, Sheaff M. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery 2003;134:827-34.
35. Reome JB, Hylind JC, Dutton RW, Dobrzanski MJ. Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clin Immunol 2004;111:69-81.
36. Carter WB, Hoying JB, Boswell C, Williams SK. HER2/neu overexpression induces endothelial cell retraction. Int J Cancer 2001;91:295-9.
37. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:1049-56.
38. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004;4:118-32.
39. Agiostratidou G, Hulit J, Phillips GR, Hazan RB. Differential cadherin expression: potential markers for epithelial to mesenchymal transformation during tumor progression. J Mammary Gland Biol Neoplasia 2007;12:127-33.
40. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-29.
41. Mohammadizadeh F, Ghasemibasir H, Rajabi P, Naimi A, Eftekhari A, Mesbah A. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma. Cancer Biomark 2009;5:1-8.
42. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003;5:R217-22.
43. Waldhauer I, Steinle A. NK cells and cancer immuno-surveillance. Oncogene 2008;27:5932-43.
44. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
45. Girardi M, Oppenheim DE, Steele CR. Regulation of cutaneous malignancy by γδ T cells. Science 2001;294:605-9.